Apoptosis in the development and treatment of cancer

被引:316
作者
Gerl, R [1 ]
Vaux, DL [1 ]
机构
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia
基金
英国医学研究理事会;
关键词
D O I
10.1093/carcin/bgh283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our somatic cells are born by mitosis and almost all will die by apoptosis, a physiological process of cellular suicide. Cancers can occur when this balance is disturbed, either by an increase in cell proliferation or a decrease in cell death. The goal of cancer therapy is to promote the death of cancer cells without causing too much damage to normal cells. Our knowledge of the mechanisms of apoptosis has enhanced our understanding of how some cancers originate and progress. It has also revealed that existing cancer therapies can work in two ways, by induction of apoptosis as well as by direct toxicity. In some cases resistance to apoptosis may explain why cancer therapies fail. Novel treatments designed to exploit our knowledge of apoptotic mechanisms are under development to promote apoptosis of cancer cells and limit concurrent death of normal cells.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 108 条
  • [1] Ways of dying: multiple pathways to apoptosis
    Adams, JM
    [J]. GENES & DEVELOPMENT, 2003, 17 (20) : 2481 - 2495
  • [2] Allen SM, 2003, CANCER RES, V63, P567
  • [3] Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ
    Arnt, CR
    Chiorean, MV
    Heldebrant, MV
    Gores, GJ
    Kaufmann, SH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) : 44236 - 44243
  • [4] Apoptosis control by death and decoy receptors
    Ashkenazi, A
    Dixit, VM
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) : 255 - 260
  • [5] ASKEW DS, 1991, ONCOGENE, V6, P1915
  • [6] Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs
    Baell, JB
    Huang, DCS
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) : 851 - 863
  • [7] Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL
    Becattini, B
    Kitada, S
    Leone, M
    Monosov, E
    Chandler, S
    Zhai, DY
    Kipps, TJ
    Reed, JC
    Pellecchia, M
    [J]. CHEMISTRY & BIOLOGY, 2004, 11 (03): : 389 - 395
  • [8] Bouillet P, 2002, J CELL SCI, V115, P1567
  • [9] Brown JM, 1999, CANCER RES, V59, P1391
  • [10] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
    Capdeville, R
    Buchdunger, E
    Zimmermann, J
    Matter, A
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) : 493 - 502